Lipella Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for urological conditions, particularly those affecting the bladder. The company is engaged in advancing its proprietary drug candidates through clinical trials, aiming to address unmet medical needs in the treatment of bladder diseases such as interstitial cystitis and overactive bladder. By leveraging advanced drug delivery technologies and focusing on targeted treatment approaches, Lipella seeks to improve patient outcomes and enhance the quality of life for individuals suffering from these debilitating conditions.